Keenova Therapeutics Director Marc Yoskowitz Receives 4,406 RSUs

What Happened

• Marc J. Yoskowitz, a director of Keenova Therapeutics plc, received a grant of 4,406 restricted stock units (RSUs) on July 15, 2026. The Form 4 reports the acquisition price as $0.00 (an award/derivative grant), so no cash changed hands at grant.

Key Details

• Transaction date: July 15, 2026; filed on Form 4 July 17, 2026 (appears timely — within the typical two-business-day SEC reporting window).
• Award: 4,406 RSUs reported at $0.00 (derivative award to be settled in ordinary shares).
• Shares owned after transaction: not specified in the provided filing.
• Footnotes: (F1) Each RSU will be settled for one ordinary share upon vesting. (F2) Vesting occurs on the earlier of (i) the first anniversary of the grant date or (ii) the issuer’s next annual general meeting of shareholders.
• Remarks: Filing includes a notice to the issuer for purposes of Part V of the Companies Act 2014.

Context

• RSUs are a form of equity compensation that convert into actual shares when they vest; they are not an immediate open-market purchase or sale. Grants are commonly used for director compensation and do not necessarily indicate near-term buying or selling activity.
• Because this is an award (not a purchase or sale), it reflects compensation or retention policy rather than a direct market vote by the insider.